
Greig Rooney
CEO, CPI
Working together, innovators and manufacturers can translate scientific expertise into new products and processes that improve treatment decisions — and benefit patients.
The global fight against antimicrobial resistance (AMR) is too “broad-brush,” argues Greig Rooney, CEO of CPI, a translational research organisation that helps companies scale ideas into successful products and processes.
Faster tests mean fewer broad-spectrum antibiotics
“Too often, clinicians must start treatment before they have identified the pathogen causing the infection,” he explains. “That means giving the patient broad-spectrum antibiotics, which can negatively affect the body’s microbiome and good bacteria.” What’s needed is rapid diagnostics and tests that guide targeted treatment, reduce inappropriate antibiotic use and strengthen AMR surveillance.
In its 2024–2029 national action plan for confronting antimicrobial resistance, the UK Government set a goal for the life sciences sector to be “actively engaging and responding to the demand for new tools, technologies and interventions for tackling AMR.” It includes a commitment to making rapid, accurate diagnostic testing “available when and where needed so that antimicrobials go only to patients who need them.”
commits government to funding research with regulators, academia and industry on vaccines, diagnostics, antimicrobials and alternative therapies
Rooney notes that CPI has an important role to play because — working across diagnostics, devices and therapeutics — it helps close the manufacturing gap by providing innovators of rapid tests and treatments with the expertise and facilities needed to successfully scale their products. “The challenge of taking an idea from concept into commercial reality is fraught with risk and technical complexity,” he says. “But if innovators consider manufacturing early in their development journey, they can identify risks and ensure their products are made more efficiently, and to the right quality and safety standards.”
A multifactorial approach to a complex issue
There is no silver bullet for AMR, so the national action plan commits government to funding research with regulators, academia and industry on vaccines, diagnostics, antimicrobials and alternative therapies. The latter includes bacteriophages: viruses that kill harmful bacteria without harming humans. “Antibiotics will remain essential going forward,” says Rooney. “But targeted therapies such as bacteriophages will have an increasing role to play.”
It’s an area of life sciences CPI is involved in. For example, Rooney highlights its work on Project GAIA, helping scientists at the University of Glasgow scale up a protein antibiotic that could treat lung infections in patients with cystic fibrosis. “Of course, any new modalities must be made more affordable,” says Rooney. “We’ve shown how innovators and CPI can work together to develop more efficient and affordable solutions for the greater good of the UK population.”
Global Cause